Capricor Therapeutics, Inc. (NASDAQ:CAPR) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR) have received an average recommendation of “Moderate Buy” from the ten brokerages that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, eight have given a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $53.6667.

A number of equities research analysts have commented on CAPR shares. Weiss Ratings restated a “sell (d-)” rating on shares of Capricor Therapeutics in a research report on Monday, June 15th. LADENBURG THALM/SH SH upgraded shares of Capricor Therapeutics to a “strong-buy” rating in a report on Thursday, June 25th. Roth Capital reiterated a “buy” rating and issued a $38.00 price objective on shares of Capricor Therapeutics in a research note on Friday, May 15th. Finally, HC Wainwright reissued a “buy” rating and set a $60.00 price objective on shares of Capricor Therapeutics in a report on Wednesday, May 13th.

Capricor Therapeutics Price Performance

CAPR opened at $19.83 on Friday. Capricor Therapeutics has a 12 month low of $4.30 and a 12 month high of $40.37. The stock has a market capitalization of $1.15 billion, a P/E ratio of -8.55 and a beta of 0.42. The business has a 50 day simple moving average of $25.47 and a 200-day simple moving average of $27.52.

Capricor Therapeutics (NASDAQ:CAPR) last announced its quarterly earnings data on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.04). Research analysts anticipate that Capricor Therapeutics will post -0.49 EPS for the current year.

Insider Transactions at Capricor Therapeutics

In other news, CFO Anthony Bergmann sold 25,000 shares of Capricor Therapeutics stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $31.70, for a total transaction of $792,500.00. Following the completion of the sale, the chief financial officer directly owned 8,223 shares in the company, valued at approximately $260,669.10. This trade represents a 75.25% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 50,000 shares of company stock valued at $1,551,658 over the last three months. Company insiders own 9.20% of the company’s stock.

Hedge Funds Weigh In On Capricor Therapeutics

Several hedge funds have recently bought and sold shares of CAPR. Suvretta Capital Management LLC acquired a new position in Capricor Therapeutics during the fourth quarter worth $51,533,000. Tang Capital Management LLC acquired a new stake in Capricor Therapeutics in the fourth quarter valued at $49,062,000. RA Capital Management L.P. purchased a new position in shares of Capricor Therapeutics in the fourth quarter valued at $43,516,000. Darwin Global Management Ltd. purchased a new position in shares of Capricor Therapeutics in the fourth quarter valued at $23,168,000. Finally, SB Capital Management Inc purchased a new position in shares of Capricor Therapeutics in the fourth quarter valued at $11,544,000. 21.68% of the stock is owned by hedge funds and other institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.